Sabadell Asabys joins the €17M Series B in our client DeepUll

Sabadell Asabys made the first investment of its new SAHII II fund in DeepUll, a Metrix Partners client, in March 2023. The investment extended DeepUll’s Series B from €13M to €17M.

Sabadell Asabys investment in DeepUll Series B

About DeepUll

DeepUll is a Barcelona medical diagnostics company developing culture-free diagnostic solutions for sepsis and other acute infections. It was founded in 2020 by the founders of STAT-Dx, which was sold to QIAGEN in 2018. The company is based in the Barcelona Science Park.

Sepsis is the body’s extreme response to infection and a leading cause of death in hospitals. Treatment depends on identifying the pathogen quickly, but standard blood cultures can take days. DeepUll’s automated device aims to identify pathogens directly from blood, without culture, so that doctors can choose the right treatment sooner.

The Series B

DeepUll announced a €13M Series B in October 2022, led by CDTI through its Innvierte programme, with Werfen, Kurma Partners, Alta Life Sciences, UI Investissement and Axis Participaciones Empresariales, as Web Capital Riesgo reported. The Sabadell Asabys investment took the round to €17M, as Expansión reported.

About Sabadell Asabys

Sabadell Asabys is a healthcare venture capital firm launched with the support of Banco Sabadell. SAHII II (Sabadell Asabys Healthcare Innovation Investments II) is its second fund. Choosing DeepUll as the fund’s first investment signals confidence in the team’s track record and in the clinical need.

Five lessons for investors in diagnostics

  1. Repeat founders reduce risk. A team that has built and sold a diagnostics company before knows the regulatory and commercial path.
  2. Regulation sets the timeline. CE marking under the EU in vitro diagnostics regulation and FDA clearance in the US determine when revenue can start.
  3. Clinical evidence sells. Hospitals buy on outcomes data. Clinical studies are a major cost and a key milestone.
  4. Instrument and consumables economics matter. Diagnostic companies often place devices and earn on test cartridges. Margin per test and installed base drive value.
  5. Corporate investors add more than money. A diagnostics group such as Werfen in the cap table brings industrial and commercial insight.

What diagnostics founders should prepare

  • A development plan with regulatory milestones and costs.
  • A clinical study plan with budget and timing.
  • Unit cost estimates for devices and consumables at scale.
  • Monthly accounts reconciled to the statutory filings, with public grants and loans shown separately.
  • A cap table and summary of all financing instruments, including public funding.

Financing deep medtech

Diagnostics development takes years and large budgets before the first sale. Companies combine venture capital, corporate investors, public programmes and venture debt. DeepUll’s financing shows that mix: venture funds and a corporate in the Series B, a public investor in CDTI, and later a €20M venture loan from the European Investment Bank. Managing several sources of capital needs strong finance and reporting, since each funder has its own conditions and reporting requirements.

Investors in this type of company look at the total funding plan to reach regulatory approval and first revenue, not only at the current round. A clear plan that shows how each source is used, and what milestone it funds, makes the next round easier to raise.

Metrix Partners in life sciences

Metrix supports life sciences companies with finance, fundraising and non-dilutive funding. Other clients include Zymvol and VB Devices. Earlier life sciences work includes Northern Biologics and Aelix Therapeutics.